Cytek Biosciences, Inc. · Brief

Next report

4 days

Nov 4 · after closeest.Q3 FY26

Earnings

Expected move

No implied move.

Implied vs realized

8 reportsHistory

0 of 7≥ implied

avg implied: ±66.4%
avg realized: ±7.7%

Feb 27 '25±37.7%▼−6.65%×0.18

May 8 '25±53.5%▼−22.82%×0.43

Aug 6 '25—▲+5.66%—

Q3 FY25±97.7%▲+13.22%×0.14

Jan 13 '26±18.6%▼−2.46%×0.13

Q1 FY26±99.8%▲+1.82%×0.02

May 7 '26±85.0%▼−6.30%×0.07

Q2 FY26±72.4%▼−0.48%×0.01

quarterimplied−100%0+100%realized×

Q2 FY26±72.4%▼−0.48%×0.01

May '26±85.0%▼−6.30%×0.07

Q1 FY26±99.8%▲+1.82%×0.02

Jan '26±18.6%▼−2.46%×0.13

Q3 FY25±97.7%▲+13.22%×0.14

Aug '25—▲+5.66%—

2 older reports

May '25±53.5%▼−22.82%×0.43

Feb '25±37.7%▼−6.65%×0.18

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 4 report · est.

Bull2 of 3

5disclosed supplier and customer ties in SEC filingsSEC filings

153managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 3

10 of 24of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

−7.87%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

CTKB report session

Suppliers 1

BDXBecton, Dickinson×0.11

× = co-movement · max 501dSource: SEC filings · market data

Latest changes

30 daysAll changes

Oct 21impliedImplied move: ±26.6% into Nov 4 earnings (Oct 21 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.